click below
click below
Normal Size Small Size show me how
Endocrine drugs
| Question | Answer |
|---|---|
| Propylthiouracil tox | skin rash,agranulocytosis, aplastic anemia, hepatotoxicity |
| methimazole tox | teratogen, skin rash, agranulocytosis, aplastic anemia |
| levothyroxine, triidothyronine | tachycardia, heat intolerance, tremors, arryhthmias |
| GH use | Turner's syndrome, gh deficiency |
| octreotide use | acromegaly, carcinoid syndrome, gastrinoma,gucagonoma |
| oxytocin use | stimulates labor, uterine contractions, milk let-down, controls uterine hemorrhage |
| ADH (desmopressin) use | CENtrAL pituitary DI |
| demeclocycline use | SIADH |
| rapid acting insulin | lispro aspart |
| intermediate acting insulin | NPH |
| long acting insulin | glargine, detemir |
| MOA of insulin | binds insulin receptor (Tyrosine kinase activity) liver: increases glucose stored as glycogen muscle: increases glycogen and protein synthesis, K+ uptake fat: aids TG storage |
| insulin tox | hypoglycemia, hypersensitivity reaction |
| insulin use | life threatening hyperkalemia, stress induced hyperglycemia, Type 1 and 2 DM, gestational diabetes |
| sulfonylureas tox | disulfiram like effects (first generation) hypoglycemia (second generation) |
| first generation sulfonyureas | tolbutamide chlorpropramide |
| second generation sulfonylureas | glyburide glimepiride glipizide |
| MOA of sulfonylureas | close K+ channel in beta cell membrane -> cell depolarizes -> triggering of insulin release via increased Ca influx |
| biguanide (metformin) | decreased glucoconeogenesis, increased glycolysis, increased peripheral glucose uptake (insulin sensitivity) |
| can be used in patietns without islet function | metformin |
| contraindicated in renal failure | metformin |
| weight gain, edema, hepatotoxicity, heart failrue | pioglitazone, rosiglitazone |
| glitazones/thiazolidinediones MOA | increases insulin sensitivity in peripehral tissue binds to PPAR gamma nuclear transcription regulator |
| alpha glucosidase inhibitors | acarbose, miglitol |
| inhibits intestinal brush border alpha glucosidases. Delayed sugar hydrolysis and glucose absorption -> decreased postprandial hyperglycemia | acarbose, miglitol |
| pramlintide | hypoglycemia, nausea, diarrhea |
| pramlintide MOA | decreases glucagon |
| exenatide | increases insulin, decreases glucagon release |
| pancreatitis | exenatide |